Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL).

Authors :: Melani, C. J.
Lakhotia, R.
Pittaluga, S.
Phelan, J. D.
Yang, Y.
Davies‐Hill, T.
Simard, J.
Muppidi, J.
Huang, D. W.
Thomas, C. J.
Ceribelli, M.
Tosto, F. A.
Pradhan, A.
Juanitez, A. M.
Rimsza, L. M.
Jacob, A.
Simmons, H.
Steinberg, S. M.
Jaffe, E. S.
Staudt, L. M.
Source :: Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p582-584, 3p
Publication Year :: 2023
Abstract: B Methods: b R/R and TN MCL pts with adequate organ function were eligible. B Introduction: b MCL is incurable with standard chemotherapy. Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL). [Extracted from the article]

Subjects :: MANTLE cell lymphoma
LENALIDOMIDE
VENETOCLAX
REFRACTORY materials
PREDNISONE

Full Text Access

Tools